Serum Free Light Change in Multiple Myeloma

Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)

NCT00702247 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain

NCT02946333 ·Status: COMPLETED

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

NCT00546988 ·Status: UNKNOWN ·Phase: PHASE3

Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients

NCT06457464 ·Status: NOT_YET_RECRUITING

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

NCT00551928 ·Status: COMPLETED ·Phase: PHASE3

Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma

NCT05190263 ·Status: COMPLETED

Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care

NCT04111809 ·Status: TERMINATED

A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice

NCT04659798 ·Status: COMPLETED

Immune Profiling in Multiple Myeloma

NCT04135079 ·Status: COMPLETED

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies

NCT02997813 ·Status: COMPLETED

Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

NCT05271630 ·Status: ACTIVE_NOT_RECRUITING

Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma

NCT03848676 ·Status: COMPLETED

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

NCT02215980 ·Status: COMPLETED ·Phase: PHASE3

A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain

NCT03602755 ·Status: COMPLETED

Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

NCT03190525 ·Status: ACTIVE_NOT_RECRUITING

Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients

NCT01160107 ·Status: COMPLETED ·Phase: PHASE2

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

NCT00555100 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

NCT04144387 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Assessing Free Immunoglobulin Light Chains in Patients With Myeloma

NCT00301275 ·Status: COMPLETED

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Discontinuation Study

NCT05866757 ·Status: RECRUITING ·Phase: NA

Immunomonitoring and Multiple Myeloma: Impact of Lenalidomide on Immune Checkpoint Expression

NCT04872023 ·Status: COMPLETED ·Phase: NA

A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT06126237 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Quality of Life the Danish Multiple Myeloma Patients

NCT02892383 ·Status: COMPLETED